Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radalbuvir
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Radalbuvir is an experimental antiviral small molecule developed by Gilead Sciences for the treatment of hepatitis C virus (HCV) infection. It acts as a non-nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, specifically binding to thumb site II of the enzyme. Radalbuvir selectively inhibits HCV genotype 1 replication and demonstrates high metabolic stability in preclinical models. The drug was evaluated in clinical trials for chronic hepatitis C but development has been discontinued[1][3][4][7].
- Other names
- 1314795-11-3UNII-273K4V0SPCUNII273K4V0SPCUNII 273K4V0SPC
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on radalbuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radalbuvir.